AP1214A - Composition comprising 5-[4-[2-(n-methyl-n-2-pyridyl)amino) ethoxy} benzyl} thiazolidine-2, 4-dione. - Google Patents

Composition comprising 5-[4-[2-(n-methyl-n-2-pyridyl)amino) ethoxy} benzyl} thiazolidine-2, 4-dione. Download PDF

Info

Publication number: AP1214A
Authority: AP; ARIPO
Prior art keywords: pharmaceutically acceptable; compound; composition; acceptable form; composition according
Prior art date: 1997-06-05

Application number

APAP/P/1999/001696A

Other languages

English (en)

Other versions

AP9901696A0 (en

Inventor

Jai Patel

Hamish Ross

Jeffrey Roger Granett

Robin Price

Paul Nigel Wray

Original Assignee

Smithkline Beecham Plc

Smithkline Beecham Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-06-05

Filing date

1998-06-02

Publication date

2003-10-08

1997-06-18 Priority claimed from GBGB9712851.6A external-priority patent/GB9712851D0/en

1998-06-02 Application filed by Smithkline Beecham Plc, Smithkline Beecham Corp filed Critical Smithkline Beecham Plc

1999-12-31 Publication of AP9901696A0 publication Critical patent/AP9901696A0/xx

2003-10-08 Application granted granted Critical

2003-10-08 Publication of AP1214A publication Critical patent/AP1214A/en

Links

239000000203 mixture Substances 0.000 title claims abstract description 101
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 title description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 title description 2
150000001875 compounds Chemical class 0.000 claims abstract description 93
238000000034 method Methods 0.000 claims abstract description 34
239000003937 drug carrier Substances 0.000 claims abstract description 23
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 11
239000012141 concentrate Substances 0.000 claims description 12
229940080313 sodium starch Drugs 0.000 claims description 8
229920002678 cellulose Polymers 0.000 claims description 6
239000001913 cellulose Substances 0.000 claims description 6
WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims description 5
229960001021 lactose monohydrate Drugs 0.000 claims description 5
238000004519 manufacturing process Methods 0.000 claims description 4
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 4
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 3
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 claims 1
AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 claims 1
241000237518 Arion Species 0.000 claims 1
229940031705 hydroxypropyl methylcellulose 2910 Drugs 0.000 claims 1
238000002360 preparation method Methods 0.000 abstract description 7
239000003814 drug Substances 0.000 abstract description 2
206010012601 diabetes mellitus Diseases 0.000 description 15
239000003826 tablet Substances 0.000 description 15
235000008504 concentrate Nutrition 0.000 description 10
208000001072 type 2 diabetes mellitus Diseases 0.000 description 9
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
239000003981 vehicle Substances 0.000 description 6
206010022489 Insulin Resistance Diseases 0.000 description 5
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
235000010980 cellulose Nutrition 0.000 description 5
239000008187 granular material Substances 0.000 description 5
239000008101 lactose Substances 0.000 description 5
229960001375 lactose Drugs 0.000 description 5
229920000609 methyl cellulose Polymers 0.000 description 5
239000001923 methylcellulose Substances 0.000 description 5
235000010981 methylcellulose Nutrition 0.000 description 5
150000003839 salts Chemical class 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
229920000168 Microcrystalline cellulose Polymers 0.000 description 4
239000007788 liquid Substances 0.000 description 4
235000019359 magnesium stearate Nutrition 0.000 description 4
150000002688 maleic acid derivatives Chemical class 0.000 description 4
235000019813 microcrystalline cellulose Nutrition 0.000 description 4
239000008108 microcrystalline cellulose Substances 0.000 description 4
229940016286 microcrystalline cellulose Drugs 0.000 description 4
239000000546 pharmaceutical excipient Substances 0.000 description 4
ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical class O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 3
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
239000011230 binding agent Substances 0.000 description 3
238000007796 conventional method Methods 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
239000000314 lubricant Substances 0.000 description 3
238000002156 mixing Methods 0.000 description 3
238000007911 parenteral administration Methods 0.000 description 3
239000000600 sorbitol Substances 0.000 description 3
235000010356 sorbitol Nutrition 0.000 description 3
235000020357 syrup Nutrition 0.000 description 3
239000006188 syrup Substances 0.000 description 3
241000220479 Acacia Species 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
206010018429 Glucose tolerance impaired Diseases 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
206010020772 Hypertension Diseases 0.000 description 2
235000010643 Leucaena leucocephala Nutrition 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
208000008589 Obesity Diseases 0.000 description 2
-1 capsuies Substances 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
239000007884 disintegrant Substances 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
239000000945 filler Substances 0.000 description 2
238000011049 filling Methods 0.000 description 2
238000009501 film coating Methods 0.000 description 2
239000007888 film coating Substances 0.000 description 2
238000009472 formulation Methods 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
208000017169 kidney disease Diseases 0.000 description 2
239000000463 material Substances 0.000 description 2
235000020824 obesity Nutrition 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
239000008213 purified water Substances 0.000 description 2
235000020354 squash Nutrition 0.000 description 2
239000000725 suspension Substances 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
208000000103 Anorexia Nervosa Diseases 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
208000032841 Bulimia Diseases 0.000 description 1
206010006550 Bulimia nervosa Diseases 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
208000007342 Diabetic Nephropathies Diseases 0.000 description 1
239000004150 EU approved colour Substances 0.000 description 1
208000030814 Eating disease Diseases 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
208000019454 Feeding and Eating disease Diseases 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
206010060378 Hyperinsulinaemia Diseases 0.000 description 1
206010020710 Hyperphagia Diseases 0.000 description 1
235000019759 Maize starch Nutrition 0.000 description 1
206010029164 Nephrotic syndrome Diseases 0.000 description 1
206010036049 Polycystic ovaries Diseases 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
239000004141 Sodium laurylsulphate Substances 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229940123464 Thiazolidinedione Drugs 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
239000003708 ampul Substances 0.000 description 1
230000003444 anaesthetic effect Effects 0.000 description 1
208000022531 anorexia Diseases 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
229940106135 cellulose Drugs 0.000 description 1
208000020832 chronic kidney disease Diseases 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
208000033679 diabetic kidney disease Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
235000014632 disordered eating Nutrition 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
239000008157 edible vegetable oil Substances 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
208000028208 end stage renal disease Diseases 0.000 description 1
201000000523 end stage renal failure Diseases 0.000 description 1
235000019441 ethanol Nutrition 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
239000003925 fat Substances 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
239000007941 film coated tablet Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
230000037406 food intake Effects 0.000 description 1
235000012631 food intake Nutrition 0.000 description 1
239000000499 gel Substances 0.000 description 1
208000004104 gestational diabetes Diseases 0.000 description 1
206010061989 glomerulosclerosis Diseases 0.000 description 1
230000002641 glycemic effect Effects 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
230000000055 hyoplipidemic effect Effects 0.000 description 1
201000001421 hyperglycemia Diseases 0.000 description 1
230000035879 hyperinsulinaemia Effects 0.000 description 1
230000001631 hypertensive effect Effects 0.000 description 1
230000002218 hypoglycaemic effect Effects 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
150000004682 monohydrates Chemical class 0.000 description 1
SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
201000009925 nephrosclerosis Diseases 0.000 description 1
239000002687 nonaqueous vehicle Substances 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
235000020830 overeating Nutrition 0.000 description 1
239000003182 parenteral nutrition solution Substances 0.000 description 1
201000010065 polycystic ovary syndrome Diseases 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
235000013772 propylene glycol Nutrition 0.000 description 1
230000003893 regulation of appetite Effects 0.000 description 1
238000007789 sealing Methods 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000012453 solvate Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
239000001593 sorbitan monooleate Substances 0.000 description 1
235000011069 sorbitan monooleate Nutrition 0.000 description 1
229940035049 sorbitan monooleate Drugs 0.000 description 1
229940032147 starch Drugs 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
238000009492 tablet coating Methods 0.000 description 1
239000002700 tablet coating Substances 0.000 description 1
239000002278 tabletting lubricant Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
231100000759 toxicological effect Toxicity 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
238000005550 wet granulation Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Diabetes (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Hematology (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Obesity (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicinal Preparation (AREA)

APAP/P/1999/001696A 1997-06-05 1998-06-02 Composition comprising 5-[4-[2-(n-methyl-n-2-pyridyl)amino) ethoxy} benzyl} thiazolidine-2, 4-dione. AP1214A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB9711683.4A GB9711683D0 (en)	1997-06-05	1997-06-05	Composition
GBGB9712851.6A GB9712851D0 (en)	1997-06-18	1997-06-18	Composition
PCT/EP1998/003478 WO1998055122A1 (en)	1997-06-05	1998-06-02	Composition comprising 5-[4-[2-(n-methyl-n-2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione

Publications (2)

Publication Number	Publication Date
AP9901696A0 AP9901696A0 (en)	1999-12-31
AP1214A true AP1214A (en)	2003-10-08

Family

ID=26311662

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
APAP/P/1999/001696A AP1214A (en)	1997-06-05	1998-06-02	Composition comprising 5-[4-[2-(n-methyl-n-2-pyridyl)amino) ethoxy} benzyl} thiazolidine-2, 4-dione.

Country Status (29)

Country	Link
EP (1)	EP0998284A1 (id)
JP (1)	JP2001521553A (id)
KR (1)	KR20010013410A (id)
CN (3)	CN1112926C (id)
AP (1)	AP1214A (id)
AR (2)	AR008198A1 (id)
AU (1)	AU8215098A (id)
BG (1)	BG104048A (id)
BR (1)	BR9810405A (id)
CA (2)	CA2333352A1 (id)
CO (1)	CO4940400A1 (id)
DZ (1)	DZ2510A1 (id)
EA (1)	EA002384B1 (id)
GB (1)	GB9711683D0 (id)
HU (1)	HUP0004070A3 (id)
ID (1)	ID24264A (id)
IL (1)	IL133074A0 (id)
MX (1)	MXPA99011322A (id)
NO (2)	NO995938L (id)
NZ (2)	NZ523725A (id)
OA (1)	OA11306A (id)
PE (1)	PE78899A1 (id)
PL (1)	PL337201A1 (id)
SK (1)	SK164899A3 (id)
TR (2)	TR200002790T2 (id)
TW (1)	TW570797B (id)
UY (1)	UY25032A1 (id)
WO (1)	WO1998055122A1 (id)
ZA (2)	ZA984826B (id)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7045519B2 (en)	1998-06-19	2006-05-16	Chiron Corporation	Inhibitors of glycogen synthase kinase 3
US20040248945A1 (en)	1999-04-23	2004-12-09	Smithkline Beecham P.L.C.	Thiazolidinedione derivative and its use as antidiabetic
AR023561A1 (es) *	1999-04-23	2002-09-04	Smithkline Beecham Corp	Una forma polimorfica del acido maleico de un derivado de tiazolidin-2, 4 diona, una composicion farmaceutica y el uso de dicho polimorfo para lafabricacion de un medicamento
HRP20010773B1 (en)	1999-04-23	2005-06-30	Smithkline Beecham P.L.C.	Thiazolidinedione derivative and its use as antidiabetic
GB0021978D0 (en)	2000-09-07	2000-10-25	Smithkline Beecham Plc	Novel pharmaceutical
GB0127805D0 (en) *	2001-11-20	2002-01-09	Smithkline Beecham Plc	Pharmaceutical composition
WO2003050112A1 (en) *	2001-12-13	2003-06-19	Smithkline Beecham Plc	Toluenesulfonate hydrates of a thiazolidinedione derivative
GB0129876D0 (en) *	2001-12-13	2002-02-06	Smithkline Beecham Plc	Novel pharmaceutical
GB0129871D0 (en) *	2001-12-13	2002-02-06	Smithkline Beecham Plc	Novel pharmaceutical
GB0130509D0 (en) *	2001-12-20	2002-02-06	Smithkline Beecham Plc	Novel pharmaceutical
US7435741B2 (en)	2006-05-09	2008-10-14	Teva Pharmaceutical Industries, Ltd.	2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
ES2294980T1 (es) *	2006-05-09	2008-04-16	Teva Pharmaceutical Industries Ltd.	Acido 2-n-(5-((4-(2-(metil-2-piridinilamino)etoxi)fenil)metil)-2,4-tiazolidindiona)-butanodioico, procedimientos de preparacion y composiciones con maleato de rosiglitazona.
WO2015008234A1 (en) *	2013-07-17	2015-01-22	Glenmark Pharmaceuticals S.A.	Bicyclic heterocyclic compounds as ror gamma modulators

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1994005659A1 (en) *	1992-09-05	1994-03-17	Smithkline Beecham Plc	Substituted thiazolidinedione derivatives
WO1995021608A1 (en) *	1994-02-10	1995-08-17	Smithkline Beecham Plc	Use of insulin sensitisers for treating renal diseases
WO1997005875A2 (en) *	1995-08-10	1997-02-20	Warner-Lambert Company	A method of reducing the amount of exogenous insulin administered to a patient having noninsulin-dependent diabetes mellitus

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE186724T1 (de) *	1987-09-04	1999-12-15	Beecham Group Plc	Substituierte thiazolidindionderivate
WO1997018811A1 (en) *	1995-11-17	1997-05-29	Warner-Lambert Company	A method of treating myotonic dystrophy
NZ314406A (en) *	1996-03-18	2000-12-22	Sankyo Co	Treatment or prophylaxis of pancreatitis with a medicament containing an insulin sensitiser including oxazoles and thiazoles
AU3552697A (en) *	1996-07-12	1998-02-09	Smithkline Beecham Plc	Novel treatment of leptine resistance

1997
- 1997-06-05 GB GBGB9711683.4A patent/GB9711683D0/en active Pending
1998
- 1998-06-02 SK SK1648-99A patent/SK164899A3/sk unknown
- 1998-06-02 CA CA002333352A patent/CA2333352A1/en not_active Abandoned
- 1998-06-02 BR BR9810405-5A patent/BR9810405A/pt not_active IP Right Cessation
- 1998-06-02 PL PL98337201A patent/PL337201A1/xx unknown
- 1998-06-02 CA CA002292629A patent/CA2292629C/en not_active Expired - Fee Related
- 1998-06-02 EA EA199901116A patent/EA002384B1/ru not_active IP Right Cessation
- 1998-06-02 WO PCT/EP1998/003478 patent/WO1998055122A1/en not_active Ceased
- 1998-06-02 TR TR2000/02790T patent/TR200002790T2/xx unknown
- 1998-06-02 KR KR19997011411A patent/KR20010013410A/ko not_active Ceased
- 1998-06-02 EP EP98932144A patent/EP0998284A1/en not_active Withdrawn
- 1998-06-02 JP JP50158799A patent/JP2001521553A/ja not_active Ceased
- 1998-06-02 AP APAP/P/1999/001696A patent/AP1214A/en active
- 1998-06-02 TR TR1999/02963T patent/TR199902963T2/xx unknown
- 1998-06-02 MX MXPA99011322A patent/MXPA99011322A/es unknown
- 1998-06-02 IL IL13307498A patent/IL133074A0/xx unknown
- 1998-06-02 CN CN98805686A patent/CN1112926C/zh not_active Expired - Lifetime
- 1998-06-02 CN CNA2003101199090A patent/CN1526391A/zh active Pending
- 1998-06-02 NZ NZ523725A patent/NZ523725A/en unknown
- 1998-06-02 AU AU82150/98A patent/AU8215098A/en not_active Abandoned
- 1998-06-02 HU HU0004070A patent/HUP0004070A3/hu unknown
- 1998-06-02 ID IDW991520A patent/ID24264A/id unknown
- 1998-06-03 DZ DZ980120A patent/DZ2510A1/xx active
- 1998-06-04 AR ARP980102649A patent/AR008198A1/es not_active Application Discontinuation
- 1998-06-04 AR ARP980102650A patent/AR015120A1/es not_active Application Discontinuation
- 1998-06-04 CO CO98031614A patent/CO4940400A1/es unknown
- 1998-06-04 UY UY25032A patent/UY25032A1/es not_active IP Right Cessation
- 1998-06-04 ZA ZA9804826A patent/ZA984826B/xx unknown
- 1998-06-04 ZA ZA9811572A patent/ZA9811572B/xx unknown
- 1998-06-05 PE PE1998000466A patent/PE78899A1/es not_active Application Discontinuation
- 1998-10-23 TW TW087117536A patent/TW570797B/zh not_active IP Right Cessation
1999
- 1999-12-02 OA OA9900267A patent/OA11306A/en unknown
- 1999-12-03 NO NO995938A patent/NO995938L/no not_active Application Discontinuation
- 1999-12-27 BG BG104048A patent/BG104048A/bg unknown
2001
- 2001-09-03 NZ NZ513922A patent/NZ513922A/xx unknown
2002
- 2002-11-05 CN CN02149972A patent/CN1430959A/zh active Pending
2004
- 2004-02-20 NO NO20040738A patent/NO20040738L/no not_active Application Discontinuation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1994005659A1 (en) *	1992-09-05	1994-03-17	Smithkline Beecham Plc	Substituted thiazolidinedione derivatives
WO1995021608A1 (en) *	1994-02-10	1995-08-17	Smithkline Beecham Plc	Use of insulin sensitisers for treating renal diseases
WO1997005875A2 (en) *	1995-08-10	1997-02-20	Warner-Lambert Company	A method of reducing the amount of exogenous insulin administered to a patient having noninsulin-dependent diabetes mellitus

Also Published As

Publication number	Publication date
CA2292629C (en)	2004-01-06
MXPA99011322A (es)	2004-12-02
BG104048A (bg)	2000-07-31
EA002384B1 (ru)	2002-04-25
NO20040738L (no)	2000-02-02
EA199901116A1 (ru)	2000-06-26
NO995938D0 (no)	1999-12-03
NO995938L (no)	2000-02-02
AR015120A1 (es)	2001-04-18
NZ513922A (en)	2001-09-28
AR008198A1 (es)	1999-12-29
TW570797B (en)	2004-01-11
AU8215098A (en)	1998-12-21
WO1998055122A1 (en)	1998-12-10
BR9810405A (pt)	2000-08-29
JP2001521553A (ja)	2001-11-06
KR20010013410A (ko)	2001-02-26
CN1259050A (zh)	2000-07-05
NZ523725A (en)	2004-09-24
HUP0004070A2 (hu)	2002-02-28
CA2292629A1 (en)	1998-12-10
CN1526391A (zh)	2004-09-08
PL337201A1 (en)	2000-08-14
CA2333352A1 (en)	1998-12-10
GB9711683D0 (en)	1997-08-06
CN1112926C (zh)	2003-07-02
ZA984826B (en)	1999-08-03
TR200002790T2 (tr)	2001-11-21
CO4940400A1 (es)	2000-07-24
HUP0004070A3 (en)	2002-03-28
IL133074A0 (en)	2001-03-19
TR199902963T2 (xx)	2000-02-21
DZ2510A1 (fr)	2003-01-25
PE78899A1 (es)	1999-10-22
ID24264A (id)	2000-07-13
OA11306A (en)	2003-10-22
ZA9811572B (en)	1999-07-22
CN1430959A (zh)	2003-07-23
SK164899A3 (en)	2000-11-07
AP9901696A0 (en)	1999-12-31
EP0998284A1 (en)	2000-05-10
UY25032A1 (es)	1998-11-26

Publication	Publication Date	Title
EP0996444B1 (en)	2007-03-07	Treatment of diabetes with thiazolidinedione and metformin
CA2292629C (en)	2004-01-06	Composition comprising 5-[4-[2-(n-methyl-n-2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione
AP1287A (en)	2004-06-26	Treatment of diabetes with rosiglitazone and insulin.
US20040082621A1 (en)	2004-04-29	Composition comprising 5-[4-[2-(N-methyl-N-2-pyridyl)amino)ethoxy]benzyl] thiazolidine-2,4-dione
EP0998291B1 (en)	2007-07-11	Treatment of diabetes with thiazolidinedione and sulphonylurea
CA2294385C (en)	2007-06-05	Treatment of diabetes with thiazolidinedione and sulphonylurea
US20040106543A1 (en)	2004-06-03	Treatment of diabetes with rosiglitazone and insulin
AU9513401A (en)	2002-01-17	Composition comprising 5-(4-(2-(N-methyl-N-2-pyridyl) amino)ethoxy)benzyl)thiazolidine-2,4-dione
AU783539B2 (en)	2005-11-10	Treatment of diabetes with thiazolidinedione and sulphonylurea
AU778947B2 (en)	2004-12-23	Treatment of diabetes with thiazolidinedione and metformin
CZ432299A3 (cs)	2000-08-16	Kompozice obsahující 5-[4-[2-(N-methyl-N-(2- pyridyI)amino)ethoxy]benzyl]thiazolidin-2,4-dion
NZ518076A (en)	2004-02-27	5-[4-[2-(N-methyl-N-(2- pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (BRL49653) for treating non-insulin dependent diabetes (NIDDM)
AU1552102A (en)	2002-03-28	Treatment of diabetes with rosiglitazone and insulin
HK1028200B (en)	2007-10-05	Treatment of diabetes with thiazolidinedione and sulphonylurea
HK1029272B (en)	2007-12-07	Treatment of diabetes with thiazolidinedione and sulphonylurea
MXPA99012065A (en)	2000-08-01	Treatment of diabetes with rosiglitazone and insulin
HK1028193B (en)	2008-01-25	Treatment of diabetes with thiazolidinedione and metformin
CZ9904579A3 (cs)	2001-06-13	Léčivo pro léčbu diabetes mellitus a stavů spojených s diabetes mellitus